Hormonal IUD (Mirena/Kyleena) and Testosterone Interaction: What Women Need to Know

Why Women Are Using Both a Hormonal IUD and Testosterone

The combination of a levonorgestrel intrauterine device and testosterone therapy is no longer unusual. Women across several life stages arrive at this pairing for reasons that make clinical sense, even if the research on their interaction is thinner than it should be.

In reproductive years, a woman may start testosterone for hypoactive sexual desire disorder (HSDD) or androgen insufficiency and want reliable contraception on top of that. The levonorgestrel IUD (Mirena 52 mg or Kyleena 19.5 mg) is one of the most effective reversible contraceptive options available, with a failure rate below 0.1% per year.

In perimenopause, the picture shifts. Irregular cycles, worsening HSDD, and the need for endometrial protection during low-dose estrogen therapy often bring both agents into the same prescription list at once. The levonorgestrel IUD is endorsed by ACOG as an option for endometrial protection during perimenopausal hormone therapy.

In postmenopause, the scenario is less common but not rare. Some postmenopausal women on combined estrogen-testosterone therapy retain an IUD placed just before menopause for endometrial protection during the menopausal transition.

Understanding how these two agents interact requires separating pharmacokinetic questions (does one change how the other is metabolized?) from pharmacodynamic questions (do they produce overlapping or opposing biological effects?). The answers are meaningfully different.

How Levonorgestrel and Testosterone Are Each Metabolized

Both agents travel through overlapping metabolic pathways, which matters for women who also take enzyme-inducing medications or who have hepatic conditions.

Levonorgestrel IUD: Systemic Exposure Is Low but Real

The Mirena 52 mg system releases approximately 20 mcg of levonorgestrel per day initially, declining to about 10 mcg per day after five years. Kyleena 19.5 mg releases approximately 9 mcg per day initially. These are small amounts compared to oral progestin-only pills, but serum levels are detectable.

Levonorgestrel is metabolized primarily by CYP3A4 in the liver, with minor contributions from CYP3A5. It is a substrate, not a meaningful inhibitor or inducer, of CYP3A4 at these serum concentrations. Glucuronide and sulfate conjugates are the primary excretory forms.

Testosterone in Women: CYP2C19 and CYP3A4

Exogenous testosterone in women is metabolized via CYP3A4 (to androstenedione and then estrone) and CYP2C19 (to estradiol). Testosterone is also a substrate of P-glycoprotein (P-gp), which can become relevant when P-gp inhibitors or inducers are co-prescribed.

Because both levonorgestrel and testosterone share CYP3A4 as a metabolic pathway, strong CYP3A4 inhibitors (such as fluconazole or ritonavir) may modestly raise serum levels of both. Strong inducers (rifampin, carbamazepine, topiramate) may reduce efficacy of both. This is not a direct drug-drug interaction between the IUD and testosterone themselves, but a shared vulnerability worth noting if you add a third drug to the mix.

The Direct PK Interaction: Not Clinically Confirmed

At the doses used clinically, no published pharmacokinetic trial has demonstrated that testosterone at female-range doses (0.5 to 10 mg per day) meaningfully raises or lowers serum levonorgestrel concentrations, or vice versa. The FDA prescribing information for Mirena does not list testosterone as an interacting drug. The absence of a confirmed PK interaction is reassuring, but the evidence gap in women is real: most drug interaction data has been generated in male subjects or in vitro, and direct trials in women combining IUD-released LNG with female-dose testosterone do not exist in the published literature.

Pharmacodynamic Overlaps: Where the Real Risks Live

The more important clinical story is pharmacodynamic. Both levonorgestrel and testosterone exert androgenic and lipid-modifying effects, and those effects compound each other in ways that require monitoring.

Androgenic Effects of Levonorgestrel

Levonorgestrel is a 19-nortestosterone derivative with measurable androgenic activity. Its androgen receptor binding affinity is approximately 45% relative to the reference androgen methyltrienolone. At IUD-released concentrations, androgenic side effects are uncommon but not zero: acne and mild hirsutism have been reported in clinical trials of the Mirena system.

When you add exogenous testosterone on top of this, the total androgenic load on the body rises. Women with PCOS who are already hyperandrogenic carry a higher baseline, so the combined androgenic stimulus from IUD-released LNG plus testosterone therapy may push acne, seborrhea, or hirsutism to a level that requires dose adjustment of one or both agents.

Lipid Profiles: A Compound Effect

Both agents adversely affect high-density lipoprotein (HDL) cholesterol.

Testosterone therapy in women, even at physiologic female doses, lowers HDL in a dose-dependent fashion. A 2019 meta-analysis of testosterone therapy in women published in The Lancet Diabetes & Endocrinology found a mean HDL reduction of 4.0 mg/dL across trials, with larger reductions at supraphysiologic doses.

Levonorgestrel at oral pill doses also lowers HDL, though the IUD systemic dose is much smaller. Still, a woman combining the two should have a fasting lipid panel at baseline and again at three months after starting or changing either agent.

Polycythemia and Erythrocytosis

Testosterone stimulates erythropoiesis via increased erythropoietin production in the kidneys. The Endocrine Society Clinical Practice Guideline on testosterone therapy recommends stopping or reducing testosterone if hematocrit exceeds 50% in women. Levonorgestrel at IUD concentrations has not been independently associated with polycythemia in women, but the androgenic activity of LNG theoretically adds to the erythropoietic stimulus. Check hematocrit at baseline and at every dose adjustment.

SHBG Reduction and Free Testosterone

Both levonorgestrel and testosterone suppress sex hormone-binding globulin (SHBG). SHBG is the primary transport protein for testosterone in women. When SHBG falls, free (biologically active) testosterone rises even if total testosterone is unchanged. A study in the Journal of Clinical Endocrinology & Metabolism demonstrated that progestin-containing contraceptives, including LNG-based options, significantly reduce SHBG. If you are monitoring total testosterone without simultaneously measuring SHBG and free testosterone, you may underestimate androgenic exposure. Always check both.

Interaction Severity Rating and Clinical Bottom Line

Based on the available evidence, the levonorgestrel IUD plus testosterone combination carries a low-to-moderate pharmacodynamic interaction risk and no confirmed pharmacokinetic interaction at standard female doses. This maps roughly to a Category C or "monitor" designation in standard drug interaction severity scales.

The practical meaning: this combination is not contraindicated. It is not automatically unsafe. But it is not a pair you can prescribe and leave unmonitored.

Who This Combination Is Right For and Who Should Reconsider

Likely appropriate combinations

• Women in reproductive years using testosterone for HSDD who need contraception. The IUD provides highly effective contraception while testosterone targets libido. This is one of the cleaner use cases.
• Women in perimenopause using low-dose testosterone alongside menopausal hormone therapy, with the IUD providing endometrial protection in place of a systemic progestogen.
• Women with PCOS who need contraception AND are receiving testosterone for documented androgen insufficiency. This scenario requires careful monitoring of androgens, lipids, and hematocrit.

Combinations requiring extra caution or reconsideration

• Women with pre-existing dyslipidemia, particularly low HDL at baseline, may find that combining both androgenic agents worsens their cardiovascular lipid profile beyond acceptable limits.
• Women with polycythemia vera or a hematologic tendency toward erythrocytosis should not add testosterone without hematology input regardless of IUD status.
• Women with active liver disease face impaired metabolism of both LNG and testosterone; neither agent is appropriate in hepatic failure.
• Women with hormone-sensitive cancers, including certain breast cancers, should discuss with their oncologist before using either agent.

Pregnancy, Lactation, and Contraception: Required Reading

This section is mandatory for any drug article on WomanRx, and here it carries particular weight because testosterone is a known reproductive teratogen.

Testosterone in Pregnancy: Contraindicated

Testosterone exposure during the first trimester causes virilization of a female fetus. This includes clitoral hypertrophy, labial fusion, and ambiguous genitalia. The FDA has classified testosterone products with language equivalent to a Category X contraindication in pregnancy for this reason. The FDA prescribing information for testosterone states the drug is contraindicated in pregnant women.

The levonorgestrel IUD provides excellent contraceptive protection (failure rate <0.1% per year), which is one reason it is arguably the best contraceptive choice for a woman taking testosterone. Oral methods require perfect adherence; the IUD removes that variable entirely.

If you are taking testosterone and your IUD is removed for any reason, testosterone must be stopped immediately until effective contraception is re-established. This instruction should appear in your chart and your patient education materials.

Testosterone in Lactation

Testosterone is expressed in breast milk. Human data on infant exposure are very limited, but because testosterone is a potent androgen, breastfeeding is generally considered incompatible with maternal testosterone therapy. The FDA label for testosterone products does not recommend use in breastfeeding women.

Levonorgestrel in small amounts is found in breast milk following IUD placement. At the low systemic concentrations from an IUD, no adverse effects on breastfed infants have been documented, and ACOG considers the levonorgestrel IUD compatible with breastfeeding after the immediate postpartum period.

Postpartum Placement Timing

For women wishing to resume or begin testosterone postpartum, ensure reliable contraception is in place before the first testosterone dose. The levonorgestrel IUD can be placed at 4 to 8 weeks postpartum or immediately postpartum in some settings, giving a clear window for planning.

Monitoring Protocol for Women Using Both Agents

The following schedule reflects current Endocrine Society guidance and general principles of combined androgen monitoring, adapted for women.

Baseline Labs Before Starting

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Complete blood count with hematocrit
• Total testosterone, free testosterone, SHBG
• Liver function tests if hepatic concerns exist
• Blood pressure

At 3 Months After Starting or Adjusting Either Agent

• Repeat hematocrit. If above 50%, reduce testosterone dose or pause therapy per Endocrine Society guideline.
• Repeat fasting lipid panel
• Total and free testosterone, SHBG
• Symptom review: acne, hirsutism, mood, libido, cycle changes (if premenopausal)

Ongoing at 6 to 12 Months

• Annual fasting lipid panel minimum
• Annual CBC
• Review IUD expiration: Mirena is approved for 8 years for contraception, 5 years for HMB; Kyleena for 5 years

Female-Specific Conditions Where This Combination Is Most Relevant

PCOS

Women with PCOS are often already hyperandrogenic. Adding even low-dose testosterone to an LNG IUD increases the androgenic burden. A 2015 study in Fertility and Sterility found that LNG IUDs modestly raised free androgen index in women with PCOS compared to combined oral contraceptives, which actively suppress androgens. If PCOS is the primary diagnosis, the clinical team should weigh whether testosterone is truly necessary before adding it to an already-androgenic environment.

Hypoactive Sexual Desire Disorder (HSDD)

HSDD is the most common indication for testosterone in premenopausal and perimenopausal women. The International Society for the Study of Women's Sexual Health (ISSWSH) position statement supports the use of testosterone in postmenopausal women with HSDD at doses that bring serum testosterone to the premenopausal normal range. For premenopausal women, evidence is thinner; extrapolation from postmenopausal data is acknowledged as such in the guideline.

Perimenopause and Menopause

The perimenopausal scenario is the most common real-world use case for this drug combination. An LNG IUD placed for endometrial protection during the menopausal transition, combined with testosterone for HSDD and energy, is a medically coherent pairing. The Menopause Society's 2023 position statement on hormone therapy supports individualized hormone prescribing, including androgens, but notes evidence for testosterone is strongest in postmenopause.

Endometriosis

Women with endometriosis may use an LNG IUD for lesion suppression and symptom control. If testosterone is added for HSDD or well-being, there is no specific contraindication, but androgenic stimulation may theoretically affect endometriotic lesions. Evidence is extremely thin here. Gynecologic follow-up every 6 to 12 months is prudent.

Other Drug Interactions That Matter When You Are on Both Agents

A woman taking both a levonorgestrel IUD and testosterone should also be aware of these third-drug interactions:

• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort, topiramate): may reduce serum levels of both LNG and testosterone, potentially compromising contraceptive efficacy and androgen effect. While the IUD's contraceptive action is partly local (thickening cervical mucus and thinning endometrium), the FDA recommends not relying solely on hormonal contraceptives with strong CYP3A4 inducers.
• CYP3A4 inhibitors (fluconazole, ketoconazole, some HIV medications): may raise free testosterone and LNG serum concentrations, increasing androgenic and potentially erythropoietic effects.
• Warfarin: testosterone may potentiate warfarin anticoagulation. Monitor INR closely if a woman on both the IUD and testosterone starts warfarin.
• Insulin and oral hypoglycemics: testosterone may improve insulin sensitivity in women with PCOS, potentially requiring downward dose adjustment of insulin or metformin. A trial published in JCEM found testosterone modestly improved insulin sensitivity metrics in women with androgen deficiency.